| Field | Specification |
|---|---|
| Alternative names | Peginterferon β-1a |
| CAS no. | |
| Applications | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Peginterferon beta-1a, also written as Peginterferon β-1a, is the first pegylated interferon beta-1a molecule. It induces apoptosis in cancer cells and shows anti-tumor activity in nude mouse models, and it can be used in research on cancer and multiple sclerosis (RMS)[1].
Physical & Chemical Properties
| CAS Number | 1211327-92-2 |
|---|---|
| Signaling Pathway | Apoptosis |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with your institution's chemical hygiene plan.
In Vitro
The viability of SK-MEL-2, SK-MEL-5, MeWo and WM-266-4 tumor cells is affected by Peginterferon beta-1a (0.001-1000 ng/mL; 5 d)[1]. Peginterferon beta-1a (10, 100, and 1,000 ng/mL) triggers cell apoptosis[1].
Cell Viability Assay[1]
| Cell Line | SK-MEL-1, SK-MEL-2, SK-MEL-5, MeWo and WM-266-4 tumor cell lines |
|---|---|
| Concentration | 0.001-1000 ng/mL |
| Incubation Time | 5 d |
| Result | Inhibited the cell viability of SK-MEL-2, SK-MEL-5, MeWo and WM-266-4 tumor cells and showed an IC50 value of 2-3 ng/mL to WM-266-4 cells. |
Western Blot Analysis[1]
| Cell Line | WM-266-4 cell line |
|---|---|
| Concentration | 10, 100 and 1000 ng/mL |
| Incubation Time | 24 h |
| Result | Induced the cleavage of PARP, caspase-8, and -9, induction of TRAIL and phosphorylation of STAT1. |
In Vivo
In xenograft nude mice, Peginterferon beta-1a (0.1-1.6 mg/kg; s.c. QW/BIW/TIW for 3-4 weeks) inhibits growth of SK-MEL-1, A-375 melanoma and WM-266-4 melanoma cancers[1].
| Animal Model | Nude mice with human SK-MEL-1 and A-375 melanoma xenografts[1] |
|---|---|
| Dosage | 0.1-1.6 mg/kg |
| Administration | Subcutaneous injection; once/twice a week; for 3/4 weeks |
| Result | Significantly inhibited SK-MEL-1 tumor growth at 0.4 mg/kg (QW; 3 w) and inhibited A-375 melanoma tumors at 1.6 mg/kg (BIW; 4 w). |
| Animal Model | Nude mice with human WM-266-4 melanoma xenografts[1] |
|---|---|
| Dosage | 0.4-1.6 mg/kg |
| Administration | Subcutaneous injection; 0.4-1.6 mg/kg; once/twice/three times a week for 4 w |
| Result | The QW dose of 1.6 mg/kg and all doses given BIW and TIW induced tumor regression, with a 1.6 mg/kg QW dose induced significant tumor inhibition relative to 0.8 mg/kg QW. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
